Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
Clinical Trial Service and Epidemiological Studies Unit, Radcliffe Infirmary, University of Oxford, Oxford OX2 6HE, UK. christina.davies@ctsu.ox.ac.uk
Christina
C
Davies